Core Viewpoint - The company has achieved its first profitability and secured a significant contract worth nearly $6 billion, validating its AI pharmaceutical commercialization capabilities [1][2]. Group 1: Financial Performance - In the first half of 2025, the company reported revenue of 517 million yuan, a year-on-year increase of 403.8% [1]. - The adjusted net profit reached 141.6 million yuan, marking the first half-year profitability for the company [1]. Group 2: Strategic Partnerships - The company signed a final cooperation agreement with DoveTree Medicines LLC, initiating an end-to-end AI drug discovery strategic partnership [2]. - The agreement allows the company to receive an initial payment of $51 million, with potential milestone payments totaling up to $5.89 billion [2]. Group 3: Capital Raising and Utilization - The company completed a new round of placement, raising 2.6533 billion HKD, which represents 6.64% of the expanded issued share capital [3]. - The raised funds will be allocated as follows: 40% for product iteration and R&D enhancement, 30% for commercialization and business expansion, and 30% for investments, talent acquisition, and funding supplementation [3].